Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8049480 | 0.98 | CYP2D6 (0.97) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL8055803 | 0.90 | CYP2D6 (0.81) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| Hydrochloric Acid SCHEMBL8053388 | 0.88 | CYP2D6 (0.79) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL8048808 | 0.88 | CYP2D6 (0.79) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| Hydrochloric Acid SCHEMBL8049447 | 0.87 | CYP2D6 (0.77) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL28845273 | 0.82 | CYP2D6 (0.70) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL8597545 | 0.82 | CYP2D6 (0.70) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL17315544 | 0.82 | CYP2D6 (0.70) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL9217028 | 0.81 | CYP2D6 (0.69) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 | |
| SCHEMBL28265778 | 0.81 | CYP2D6 (0.68) | CYP2D6CYP2C19SMN1; SMN2ALDH1A1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9301958-A | — | — | None | — | — | JP | disclosed |
| EP-3849604-B1 | GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS FOR USE IN TREATING AN INFLUENZA VIRUS INFECTION | UNIV MARYLAND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220002399-A1 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3849604-A1 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | University of Maryland, Baltimore (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055798-A1 | METHODS FOR DECREASING INFLUENZA-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-03-19 | — | — | WO | disclosed |
| US-20150297591-A1 | METHODS OF TREATING PULMONARY FIBROSIS | UNIV DUKE (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297591-A1 | METHODS OF TREATING PULMONARY FIBROSIS | UNIV DUKE (US) | 2015-10-22 | — | — | US | disclosed |
| US-20130280270-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | UNIV DUKE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130280270-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | UNIV DUKE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20120045441-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | SUNDAY MARY E (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120045441-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | SUNDAY MARY E (US) | 2012-02-23 | — | — | US | disclosed |
| US-7326717-B2 | Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof | L'OREAL (FR) | 2008-02-05 | — | — | US | disclosed |
| EP-1475376-B1 | Hair composition containing a pyrimidine-n-oxide derivative and its use to stimulate keratinic fiberes growth and/or preventing their loss | OREAL (FR) | 2007-07-18 | — | — | EP | disclosed |
| US-6080750-A | FOR PROPHYLAXIS AND TREATMENT OF DISEASES CAUSED BY INFECTION BY ROTAVIRUS | NIPPON SHOJI KAISHA LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| JP-H09301958-A | NEW PYRIMIDINE COMPOUND AND ANTIROTAVIRUS AGENT | NIPPON SHOJI KK | 1997-11-25 | — | — | JP | disclosed |
| EP-0806418-A2 | Novel pyrimidine compound and anti-rotavirus agent | NIPPON SHOJI KAISHA, LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
| EP-0004173-B1 | 2,3-DIHYDROIMIDAZO (1,2-C) PYRIMIDINES, THEIR PREPARATION, FORMULATIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS | ELI LILLY AND COMPANY (US) | 1982-09-22 | — | — | EP | disclosed |
| EP-0004173-A1 | 2,3-Dihydroimidazo (1,2-c) pyrimidines, their preparation, formulations containing them and their use as pharmaceuticals | ELI LILLY AND COMPANY (US) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297591-A1 | METHODS OF TREATING PULMONARY FIBROSIS | GRPR, RXFP1, VIPR2 | CYP2D6 4885/4885CYP2C19 4672/4885SMN1; SMN2 4862/4885 |
| US-20130280270-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | GRPR, MRGPRX2, GIPR | CYP2D6 3193/4885CYP2C19 1060/4885SMN1; SMN2 3920/4885 |
| US-20120045441-A1 | METHODS OF TREATING LUNG DISEASE AND OTHER INFLAMMATORY DISEASES | GRPR, MRGPRX2, GIPR | CYP2D6 3032/4885CYP2C19 996/4885SMN1; SMN2 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.